Skip to main content

Table 2 Description about leukemia subtypes and treatment strategies

From: Effect of laminar air flow and building construction on aspergillosis in acute leukemia patients: a retrospective cohort study

Characteristics whole period phase A phase B phase C phase D p value
AML subtype
 de novo AML 49 13 6 17 13 0.646
 AML-MRC 33 13 5 8 7  
 t-MN 11 3 1 6 1  
 APL 5 1 2 1 1  
 CML-BC 1 1 0 0 0  
ALL subtype
 B-ALL 10 4 0 6 0 0.092
 T-ALL 8 0 2 3 3  
 CML-BC 3 0 1 1 1  
induction treatment for AML
 SDAC with anthracyclinea 86 21 11 31 20 0.002
 HDAC based treatmentsa 11 9 1 0 1  
 anthracycline with ATRA 5 1 2 1 1  
induction treatment for ALL
 HyperCVAD-MA 17 5 4 8 0 0.002
 other treatments 5 0 0 3 5  
  1. AML denotes acute myelogenous leukemia; AML-MRC AML with myeloid dysplasia related changes, t-MN treatment related myeloid neoplasia; APL acute promyelocytic leukemia, CML-BC chronic myeloid leukemia blast crisis, ALL acute lymphoblastic leukemia, Ph-ALL Philadelphia chromosome positive ALL, B-ALL B cell ALL, T-ALL T cell ALL, SDAC standard-dose cytarabine, HDAC high-dose cytarabine, ATRA all-trans retinoic acid, HyperCVAD-MA hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate, and cytarabine aSDAC means 100-200mg/ m2 of cytarabine and HDAC means more than 1-2g/ m2 of cytarabine